Lexaria Bioscience's EBIT per Share for the
three
months ended in Feb. 2024 was $-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.69.
During the past 3 years, the average EBIT per Share Growth Rate was 12.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 16.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -28.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Lexaria Bioscience's EBIT per Share or its related term are showing as below:
LEXX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -372.3 Med: -14.7 Max: 84.6
Current: 12.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Lexaria Bioscience was 84.60% per year. The lowest was -372.30% per year. And the median was -14.70% per year.
LEXX's 3-Year EBIT Growth Rate is ranked better than 61.86% of 1311
companies
in the Biotechnology industry
Industry Median: 3.7
vs LEXX: 12.90
The historical data trend for Lexaria Bioscience's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (NAS:LEXX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lexaria Bioscience EBIT per Share Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience (Lexaria Bioscience) Business Description
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 